Use of Alpha-adrenergic Antagonists for Lower Urinary Tract Symptoms is Not Associated with Worsening Cognitive Function

Overview

Journal Neurourol Urodyn

Date 2024 May 28

PMID 38803218

Authors

Fernanda Gabrigna Berto

J Andrew McClure

Jeffrey Campbell

Blayne Welk

Affiliations

Soon will be listed here.

Abstract

Introduction: Alpha-adrenergic antagonists are widely prescribed for lower urinary tract symptoms (LUTS), however there has been a report that their use is associated with dementia. Our objective was to investigate if new users of alpha-adrenergic antagonists with varying levels of cognitive impairment had an increased risk of cognitive decline compared to non-users.

Methods: This was a retrospective cohort study, utilizing data from the National Alzheimer's Coordinating Center (NACC) data set. After applying relevant exclusion criteria, 916 people who were newly using alpha-antagonist medications were matched with a propensity score to 916 who were not using these medications. The primary outcome was a clinically relevant cognitive decline measured by the Clinical Dementia Rating (CDR) Dementia Staging Instrument or the mini mental state examination (MMSE). Secondary outcomes included scores from other cognitive assessment tools.

Results: The matched cohorts did not differ significantly in baseline characteristics. There were no statistically significant differences in baseline or follow-up cognitive scores between those exposed and nonexposed to alpha-adrenergic antagonists. Clinically significant cognitive decline (as defined by the CDR) occurred in 9.72% of the exposed group and 8.19% of the nonexposed group. There was no observed effect of alpha-adrenergic antagonists on cognitive decline, as measured with the CDR (odds ratio [OR] 1.34, p = 0.14) or the MMSE (OR 0.98, p = 0.92). Stratified analyses by cognitive status and apolipoprotein E genotype interaction assessment also demonstrated no significant associations.

Conclusion: Alpha-adrenergic antagonists for LUTS do not appear to increase the risk of cognitive decline, offering reassurance to clinicians and patients.

References

OBryant S, Waring S, Cullum C, Hall J, Lacritz L, Massman P . Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. Arch Neurol. 2008; 65(8):1091-5. PMC: 3409562. DOI: 10.1001/archneur.65.8.1091. View

Giuliano F . Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006; 97 Suppl 2:34-8. DOI: 10.1111/j.1464-410X.2006.06104.x. View

Duan Y, Grady J, Albertsen P, Wu Z . Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf. 2018; 27(3):340-348. DOI: 10.1002/pds.4361. View

Collin B, Raju D, Katsikas S . The cognitive effects of anticholinergic drugs on apolipoprotein ε4 carriers and noncarriers in the Wisconsin Registry for Alzheimer's Prevention study. Neuropsychology. 2021; 35(2):220-231. PMC: 8366520. DOI: 10.1037/neu0000713. View

Kim C, Ko I, Kim S, Shin M, Kang Y, Cho J . Alpha1-Adrenoceptor Antagonists Improve Memory by Activating N-methyl-D-Aspartate-Induced Ion Currents in the Rat Hippocampus. Int Neurourol J. 2016; 19(4):228-36. PMC: 4703930. DOI: 10.5213/inj.2015.19.4.228. View

Frankel J, Duan Y, Albertsen P . Is Tamsulosin Linked to Dementia in the Elderly?. Curr Urol Rep. 2018; 19(9):69. DOI: 10.1007/s11934-018-0821-0. View

Sohn J, Lee S, Kwon Y, Kim J, Kim Y, Lee J . The impact of tamsulosin on cognition in Alzheimer disease with benign prostate hyperplasia: A study using the Hallym Smart Clinical Data Warehouse. Medicine (Baltimore). 2020; 99(22):e20240. DOI: 10.1097/MD.0000000000020240. View

Franco-Salinas G, de la Rosette J, Michel M . Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations. Clin Pharmacokinet. 2010; 49(3):177-88. DOI: 10.2165/11317580-000000000-00000. View

Besser L, Kukull W, Knopman D, Chui H, Galasko D, Weintraub S . Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord. 2018; 32(4):351-358. PMC: 6249084. DOI: 10.1097/WAD.0000000000000279. View

10.

Liu C, Liu C, Kanekiyo T, Xu H, Bu G . Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9(2):106-18. PMC: 3726719. DOI: 10.1038/nrneurol.2012.263. View

11.

Tae B, Jeon B, Choi H, Cheon J, Park J, Bae J . α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database. J Urol. 2019; 202(2):362-368. DOI: 10.1097/JU.0000000000000209. View

12.

Doze V, Papay R, Goldenstein B, Gupta M, Collette K, Nelson B . Long-term α1A-adrenergic receptor stimulation improves synaptic plasticity, cognitive function, mood, and longevity. Mol Pharmacol. 2011; 80(4):747-58. PMC: 3187532. DOI: 10.1124/mol.111.073734. View

13.

Morris J, Weintraub S, Chui H, Cummings J, DeCarli C, Ferris S . The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006; 20(4):210-6. DOI: 10.1097/01.wad.0000213865.09806.92. View

14.

Sandhu J, Bixler B, Dahm P, Goueli R, Kirkby E, Stoffel J . Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2023; 211(1):11-19. DOI: 10.1097/JU.0000000000003698. View

15.

de Mey C . alpha(1)-blockers for BPH: are there differences?. Eur Urol. 1999; 36 Suppl 3:52-63. DOI: 10.1159/000052349. View

16.

Szot P, White S, Greenup J, Leverenz J, Peskind E, Raskind M . Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007; 146(1):471-80. PMC: 3399726. DOI: 10.1016/j.neuroscience.2007.01.031. View

17.

Wilt T, MacDonald R, Nelson D . Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. J Urol. 2001; 167(1):177-83. View

18.

Arce Renteria M, Mobley T, Evangelista N, Medina L, Deters K, Fox-Fuller J . Representativeness of samples enrolled in Alzheimer's disease research centers. Alzheimers Dement (Amst). 2023; 15(2):e12450. PMC: 10242202. DOI: 10.1002/dad2.12450. View

19.

Nebes R, Pollock B, Perera S, Halligan E, Saxton J . The greater sensitivity of elderly APOE ε4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. Am J Geriatr Pharmacother. 2012; 10(3):185-92. PMC: 3367111. DOI: 10.1016/j.amjopharm.2012.03.003. View

20.

Latvala L, Tiihonen M, Murtola T, Hartikainen S, Tolppanen A . Use of α1-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease. Pharmacoepidemiol Drug Saf. 2022; 31(10):1110-1120. PMC: 9542191. DOI: 10.1002/pds.5503. View